Stocks CSTL Financial statements
Financial statementsCASTLE BIOSCIENCES INC financial statements
Income statement, balance sheet and cash flow statement for the last 8 fiscal years, taken from the XBRL data CASTLE BIOSCIENCES INC files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
| FY2019 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 22.8 | 51.9 | 62.6 | 94.1 | 137 | 220 | 332 | 344 |
| Cost of revenue | 5.3 | 7.31 | 9.69 | 15.8 | 32 | 45 | 60.2 | 71 |
| Gross profit | 17.5 | 44.6 | 53 | 78.3 | 105 | 175 | 272 | 273 |
| Research and development | 4.85 | 7.39 | 13.3 | 29.6 | 44.9 | 53.6 | 52 | 51.9 |
| Selling, general and administrative | 16.5 | 29.8 | 48.1 | 86.7 | 143 | 180 | 200 | 229 |
| Operating expenses | 21.3 | 37.2 | ||||||
| Operating income | -3.84 | 7.33 | -6.54 | -40.1 | -72.9 | -68 | 8.67 | -42.8 |
| Interest expense | 2.27 | 4.57 | 2.63 | 0 | 0.02 | 0.01 | 0.58 | 0.09 |
| Interest income | 0.02 | 0.31 | 0.37 | 0.07 | 3.97 | 10.6 | 12.9 | 11.8 |
| Other non-operating income | -0.27 | -2.93 | 0 | 0 | 0 | 0.14 | ||
| Income tax | 0.01 | 0.07 | 0.08 | -8.72 | -1.77 | 0.1 | 3.32 | -5.36 |
| Net income | -6.37 | 5.28 | -10.3 | -31.3 | -67.1 | -57.5 | 18.2 | -24.2 |
| EBITDA | -3.55 | 7.68 | -6.07 | -36.7 | -62.3 | -55.6 | 24.7 | -2.04 |
| EPS, basic | -5.33 | 0.35 | -0.54 | -1.24 | -2.58 | -2.14 | 0.66 | -0.83 |
| EPS, diluted | -5.33 | -0.21 | -0.54 | -1.24 | -2.58 | -2.14 | 0.62 | -0.83 |
| Shares, basic (weighted) | 1.91 | 8.58 | 18.9 | 25.1 | 26.1 | 26.8 | 27.8 | 29 |
| Shares, diluted (weighted) | 1.91 | 8.66 | 18.9 | 25.1 | 26.1 | 26.8 | 29.3 | 29 |
| Dividend per share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Balance sheet
| FY2019 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 4.48 | 98.8 | 410 | 330 | 123 | 98.8 | 120 | 117 |
| Short-term investments | 0 | 136 | 144 | 173 | 183 | |||
| Receivables | 12.1 | 14.6 | 12.8 | 17.3 | 23.5 | 38.3 | 51.2 | 43.4 |
| Inventory | 0.88 | 1.24 | 2.22 | 2.02 | 3.98 | 7.94 | 8.14 | 10.3 |
| Other current assets | 0.68 | 1.95 | 4.77 | 4.81 | 6.21 | 6.29 | 7.67 | 7.96 |
| Total current assets | 18.1 | 117 | 430 | 354 | 292 | 296 | 360 | 361 |
| Property, plant and equipment | 1.53 | 2.06 | 7.1 | 9.5 | 14.3 | 25.4 | 51.1 | 97.4 |
| Lease right-of-use assets | 0 | 7.38 | 12.2 | 12.3 | 11.6 | 14.8 | ||
| Goodwill | 0 | 10.7 | 10.7 | 10.7 | 10.7 | |||
| Intangible assets | 0 | 0 | 0 | 88.9 | 116 | 107 | 95.5 | 88.9 |
| Long-term investments | 0 | |||||||
| Other non-current assets | 0.21 | 0.14 | 1.54 | 1.72 | 1.11 | 1.44 | 1.23 | 3.77 |
| Total assets | 22.4 | 120 | 439 | 463 | 447 | 453 | 531 | 579 |
| Accounts payable | 1.45 | 1.87 | 2.1 | 2.55 | 4.73 | 10.3 | 6.9 | 18.7 |
| Accrued liabilities | 4.57 | 5.78 | 9.11 | 15.5 | 24.4 | 28.9 | 32.6 | 38.3 |
| Deferred revenue | 0 | 6.62 | 0 | |||||
| Short-term debt | 0 | 5.83 | 0 | 0 | 0.28 | 0.42 | ||
| Total current liabilities | 6.74 | 15.3 | 20.9 | 24.9 | 36.1 | 47.7 | 49.4 | 68.7 |
| Long-term debt | 24.5 | 19.3 | 0 | 0 | 9.75 | 9.64 | ||
| Lease liabilities | 0 | 6.9 | 11.5 | 14.2 | 14.3 | 25.2 | ||
| Other non-current liabilities | 1.03 | 0.12 | 0.09 | 0.03 | ||||
| Total liabilities | 32.5 | 34.6 | 23.6 | 50.8 | 48.2 | 62.1 | 75.4 | 108 |
| Total debt | 24.5 | 26.7 | 0 | 0 | 10 | 10.1 | ||
| Paid-in capital | 0.92 | 137 | 478 | 505 | 560 | 609 | 656 | 695 |
| Retained earnings | -57.5 | -52.2 | -62.5 | -93.8 | -161 | -218 | -200 | -224 |
| Other comprehensive income | 0 | -0.38 | 0.14 | 0.23 | 0.27 | |||
| Shareholders' equity | -56.6 | 85.1 | 416 | 412 | 399 | 391 | 456 | 471 |
| Total equity | -56.6 | 85.1 | 416 | 412 | 399 | 391 | 456 | 471 |
| Total liabilities and equity | 22.4 | 120 | 439 | 463 | 447 | 453 | 531 | 579 |
| Shares outstanding | 1.92 | 17.1 | 24.8 | 25.4 | 26.6 | 27.4 | 28.5 | 29.7 |
Cash flow statement
| FY2019 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|---|---|---|
| Net income | -6.37 | 5.28 | -10.3 | -31.3 | -67.1 | -57.5 | 18.2 | -24.2 |
| Depreciation and amortization | 0.29 | 0.35 | 0.47 | 3.41 | 10.5 | 12.3 | 16 | 40.8 |
| Stock-based compensation | 0.29 | 1.25 | 8.31 | 21.7 | 36.3 | 51.2 | 50.3 | 45.9 |
| Deferred income tax | 0 | 0 | 0 | -8.74 | -1.88 | -0.22 | 1.4 | -6.23 |
| Change in receivables | -8.41 | -0.9 | 1.66 | -4.63 | -6.22 | -14.9 | -12.6 | 6.88 |
| Change in inventory | -0.58 | -0.36 | -0.98 | 0.33 | -1.68 | -3.96 | -0.19 | -2.14 |
| Change in payables | 0.2 | 0.56 | 0.17 | -0.18 | 0.58 | 5.71 | -4.37 | 3.08 |
| Cash from operations | -12.3 | 7.02 | 9.87 | -19 | -41.7 | -5.63 | 64.9 | 64.3 |
| Capital expenditures | -0.28 | -0.94 | -4.75 | -3.48 | -5.63 | -13.6 | -28.3 | -36 |
| Acquisitions | 0 | -27 | 0 | 0 | ||||
| Purchases of investments | 0 | -135 | -189 | -206 | -189 | |||
| Sales and maturities of investments | 0 | 187 | 184 | 189 | ||||
| Cash from investing | -0.28 | -0.94 | -4.75 | -66.7 | -167 | -16.2 | -50.1 | -60.4 |
| Stock issued | 0.04 | 65.9 | 330 | 0 | 0.83 | 0.27 | 2.02 | 2.21 |
| Cash from financing | 15.8 | 88.3 | 306 | 5.42 | 1.52 | -2.3 | 6.14 | -6.96 |
| Net change in cash | 3.27 | 94.4 | 311 | -80.2 | -207 | -24.1 | 20.9 | -2.98 |
| Free cash flow | -12.6 | 6.08 | 5.11 | -22.5 | -47.3 | -19.2 | 36.5 | 28.3 |
| Interest paid | 1.64 | 2.21 | 1.98 | 0 | 0.02 | 0.01 | 0.43 | 0.06 |
| Income taxes paid | 0.16 | -0.15 | 0.1 | 0.02 | 0.12 | 0.2 | 2.5 | 1.6 |
Key metrics
Profitability
| Metric | Value | How it is calculated |
|---|---|---|
| Gross margin | 77.3% | Gross profit / revenue. |
| Operating margin | -9.0% | Operating income / revenue. |
| EBITDA margin | -5.9% | EBITDA (operating income + depreciation and amortization) / revenue. |
| Net margin | -5.4% | Net income / revenue. |
| FCF margin | -0.1% | Free cash flow (cash from operations - capital expenditures) / revenue. |
| Operating cash flow margin | 11.9% | Cash from operations / revenue. |
| Return on equity (ROE) | -4.1% | Net income / average shareholders' equity (opening and closing). Not shown when equity is negative. |
| Return on assets (ROA) | -3.5% | Net income / average total assets. |
| Return on invested capital (ROIC) | -6.1% | Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%. |
| R&D / revenue | 15.5% | Research and development expense / revenue. |
| SG&A / revenue | 68.2% | Selling, general and administrative expense / revenue. |
| Stock-based pay / revenue | 12.6% | Stock-based compensation (from the cash flow statement) / revenue. |
| Capex / revenue | 12.1% | Capital expenditures / revenue. |
| D&A / revenue | 3.1% | Depreciation and amortization / revenue. |
Growth
| Metric | Value | How it is calculated |
|---|---|---|
| Revenue growth, 1y | 3.7% | Revenue vs the same period a year earlier. Only from a positive base. |
| Revenue CAGR, 3y | 35.9% | Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive. |
| Revenue CAGR, 5y | 40.6% | Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive. |
| Gross profit growth, 1y | 0.5% | Gross profit vs the same period a year earlier. Only from a positive base. |
| Gross profit CAGR, 3y | 37.5% | Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive. |
| Gross profit CAGR, 5y | 38.8% | Compound annual growth of gross profit over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive. |
| Operating income growth, 1y | -593.8% | Operating income vs the same period a year earlier. Only from a positive base. |
| EBITDA growth, 1y | -108.3% | EBITDA vs the same period a year earlier. Only from a positive base. |
| Net income growth, 1y | -232.4% | Net income vs the same period a year earlier. Only from a positive base. |
| EPS growth, 1y | -233.9% | EPS vs the same period a year earlier. Only from a positive base. |
| Operating cash flow growth, 1y | -0.8% | Operating cash flow vs the same period a year earlier. Only from a positive base. |
| Operating cash flow CAGR, 5y | 45.5% | Compound annual growth of operating cash flow over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive. |
| Free cash flow growth, 1y | -22.5% | Free cash flow vs the same period a year earlier. Only from a positive base. |
| Free cash flow CAGR, 5y | 40.8% | Compound annual growth of free cash flow over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive. |
| Book value growth, 1y | 3.3% | Book value vs the same period a year earlier. Only from a positive base. |
| Book value CAGR, 3y | 5.7% | Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive. |
| Book value CAGR, 5y | 2.5% | Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive. |
| Total assets growth, 1y | 8.9% | Total assets vs the same period a year earlier. Only from a positive base. |
| Total assets CAGR, 3y | 9.0% | Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive. |
| Total assets CAGR, 5y | 5.7% | Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive. |
| Share count change, 1y | -0.9% | Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution. |
| Share count change per year, 3y | 3.6% | Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution. |
| Share count change per year, 5y | 8.9% | Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution. |
Balance sheet health
| Metric | Value | How it is calculated |
|---|---|---|
| Current ratio | 6.04x | Current assets / current liabilities. |
| Quick ratio | 5.58x | (Cash + short-term investments + receivables) / current liabilities. |
| Cash ratio | 4.72x | (Cash + short-term investments) / current liabilities. |
| Debt / equity | 0.02x | Total debt / shareholders' equity. Not shown when equity is negative. |
| Debt / assets | 1.8% | Total debt / total assets. |
| Liabilities / assets | 16.2% | Total liabilities / total assets. |
| Net debt | -$256.7M | Total debt - cash - short-term investments. Negative means more cash than debt. |
| Interest coverage | -85.6x | Operating income / interest expense. |
| Working capital | $284.6M | Current assets - current liabilities. |
| Goodwill and intangibles / assets | 16.9% | (Goodwill + intangible assets) / total assets. |
| Tangible book value | $374.9M | Shareholders' equity - goodwill - intangible assets. |
Efficiency
| Metric | Value | How it is calculated |
|---|---|---|
| Asset turnover | 0.64x | Revenue / average total assets. |
| Fixed asset turnover | 3.41x | Revenue / average property, plant and equipment. |
| Inventory turnover | 7.68x | Cost of revenue / average inventory. |
| Days inventory | 48 days | 365 x average inventory / cost of revenue. |
| Receivables turnover | 7.39x | Revenue / average receivables. |
| Days sales outstanding | 49 days | 365 x average receivables / revenue. |
| Days payables | 43 days | 365 x average accounts payable / cost of revenue. |
| Cash conversion cycle | 53 days | Days inventory + days sales outstanding - days payables. |
| Capex / operating cash flow | 101.1% | Capital expenditures / cash from operations, when that is positive. |
Per share
| Metric | Value | How it is calculated |
|---|---|---|
| EPS, diluted | -$0.64 | Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS. |
| Revenue per share | $11.75 | Revenue / diluted weighted shares. |
| FCF per share | -$0.02 | Free cash flow / diluted weighted shares. |
| Operating cash flow per share | $1.40 | Cash from operations / diluted weighted shares. |
| Book value per share | $15.41 | Shareholders' equity / shares outstanding (diluted weighted shares when not reported). |
| Tangible book per share | $12.29 | Tangible book value / shares outstanding. |
| Cash per share | $8.75 | (Cash + short-term investments) / shares outstanding. |
Valuation
| Metric | Value | How it is calculated |
|---|---|---|
| Market cap | $1.09B | Share price x shares outstanding. |
| Enterprise value | $837.2M | Market cap + total debt - cash - short-term investments. |
| P/S | 3.06x | Market cap / revenue. |
| P/B | 2.33x | Market cap / shareholders' equity. Only when equity is positive. |
| Price / tangible book | 2.92x | Market cap / tangible book value, when positive. |
| P/OCF | 25.7x | Market cap / cash from operations, when positive. |
| EV/Sales | 2.34x | Enterprise value / revenue. |
| FCF yield | -0.0% | Free cash flow / market cap. |
| Earnings yield | -1.8% | Net income / market cap (the inverse of P/E). |
What was CASTLE BIOSCIENCES INC's revenue in fiscal 2025?
CASTLE BIOSCIENCES INC reported revenue of $344.2M for fiscal 2025, 3.7% higher than the year before.
Was CASTLE BIOSCIENCES INC profitable in fiscal 2025?
No. It reported a net loss of $24.2M.
How much free cash flow did CASTLE BIOSCIENCES INC generate in fiscal 2025?
Cash from operations of $64.3M minus capital expenditures of $36.0M left free cash flow of $28.3M.